Animab

TLDR

Animab is a Ghent-based VIB/UGent/VUB spin-off developing oral monoclonal antibodies for livestock health, raising EUR 25.4M total including a EUR 10M Series B in July 2025.

Overview

Founded in Ghent in 2020 as a spin-off from VIB, UGent, and VUB, Animab is developing a proprietary platform for delivering monoclonal antibodies orally to livestock. Conventional antibody therapies require injection, which is impractical at agricultural scale. Animab's technology enables therapeutic proteins to survive the digestive tract and reach systemic circulation, opening a new administration route for biologics in veterinary medicine.

The company raised EUR 10M in a Series B round in July 2025, bringing total funding to EUR 25.4M. The round supports continued clinical development of lead programs targeting major infectious diseases in poultry and pigs.

Animab operates within the dense Ghent biotech and agri-innovation cluster, benefiting from proximity to UGent's veterinary and life sciences research capabilities.

Funding History

• Series B, EUR 10M, Jul 2025
• Total raised: EUR 25.4M